Changes to certain s100 programs
Page last updated: 23 January 2020
On 1 January 2020, changes were made to the Pharmaceutical Benefits Scheme (PBS) restrictions for growth hormone treatment in adults, which set out the eligibility requirements for PBS subsidy, to provide additional clarity and improved access to growth hormone treatment. The following Frequently Asked Questions document provides information about the growth hormone program:
On 1 February 2019, revised eligibility restrictions to PBS subsidised paediatric growth hormone treatment took effect. The eligibility restriction changes relate to:
- revised height percentile thresholds;
- growth velocity percentile for bone age and sex;
- clarification of definitions within the restrictions; and
- streamlining the way associated growth data requirements are specified within the prescriber instructions.
Since 2015, changes have been made to certain Section 100 (s100) programs under the PBS. These changes, which include the introduction of community access arrangements for a number of medicines available under the Highly Specialised Drugs Program, are recommended by the Pharmaceutical Benefits Advisory Committee. The Frequently Asked Questions documents below outline the changes made and have been developed to assist prescribers, suppliers and patients.
- PBS Growth Hormone Program (Paediatric Use) 1 February 2019 Listing Changes Quick Reference Guide for Prescribers (PDF 222KB) - (Word 38KB
- Attachment to Growth Hormone Program (Paediatric Use) FAQs - Dose and Cartridge Quantity Calculator (updated 1 January 2019) (Excel 82 KB)
- Botulinum Toxin Program - Frequently Asked Questions (FAQ) (PDF 184KB) - (Word 540KB) - updated January 2020
- New options for Clozapine maintenance supply (PDF 132KB) - (Word 514KB)
- New options for HIV and Hepatitis B medicine supply (PDF 110KB) - (Word 515KB)
- In Vitro Fertilisation (IVF) medicines (PDF 476KB) - (Word 514KB)